ESBATech is a Zurich, Switzerland based company of Novartis and part of the Ophthalmology Disease Area research team of the Novartis Institutes for BioMedical Research (NIBR). ESBATech has proprietary antibody fragment technology and strong expertise in biologics research and development up to clinical Proof-of-Concept. It couples its capabilities with pathways research, biologics technologies, and other platforms in NIBR and Alcon to develop new and effective treatments for a wide range of sight-threatening eye diseases with high unmet need, including age-related macular degeneration, diabetic retinopathy, uveitis, glaucoma and dry eye.
ESBATech has several clinical and preclinical stage programs ongoing. Its most advanced antibody fragment is RTH258 (ESBA1008) which is an anti-VEGF in Phase 3 development in neovascular age-related macular degeneration. Furthermore LME636 (ESBA1622), an anti-TNF antibody fragment is in Phase 2 development for topical use in dry eye and uveitis. For more information visit clinicaltrials.gov.